700 related articles for article (PubMed ID: 17536871)
1. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
2. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
[TBL] [Abstract][Full Text] [Related]
4. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
5. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
[TBL] [Abstract][Full Text] [Related]
8. Administration of aerosolized antibiotics in cystic fibrosis patients.
Moss RB
Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
[TBL] [Abstract][Full Text] [Related]
10. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
15. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
[TBL] [Abstract][Full Text] [Related]
16. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
[TBL] [Abstract][Full Text] [Related]
17. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
18. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
19. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Quittner AL; Buu A
Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]